New York Life Investment Management LLC bought a new position in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 20,495 shares of the company’s stock, valued at approximately $2,244,000.
Several other large investors have also recently bought and sold shares of PPH. Royal Bank of Canada raised its stake in VanEck Pharmaceutical ETF by 846.9% during the 1st quarter. Royal Bank of Canada now owns 361,001 shares of the company’s stock valued at $37,501,000 after purchasing an additional 322,878 shares during the last quarter. Bank of America Corp DE boosted its holdings in VanEck Pharmaceutical ETF by 139.3% in the 1st quarter. Bank of America Corp DE now owns 143,609 shares of the company’s stock valued at $14,918,000 after purchasing an additional 83,598 shares during the period. Fluent Financial LLC acquired a new stake in VanEck Pharmaceutical ETF in the 2nd quarter worth $4,264,000. Avior Wealth Management LLC acquired a new stake in VanEck Pharmaceutical ETF in the 3rd quarter worth $1,685,000. Finally, Commonwealth Equity Services LLC acquired a new stake in VanEck Pharmaceutical ETF in the 3rd quarter worth $1,171,000.
VanEck Pharmaceutical ETF Stock Performance
Shares of NASDAQ:PPH traded up $1.35 on Friday, hitting $122.65. 193,783 shares of the company were exchanged, compared to its average volume of 320,706. The company’s 50 day moving average price is $113.65 and its two-hundred day moving average price is $108.68. VanEck Pharmaceutical ETF has a one year low of $97.52 and a one year high of $123.53. The firm has a market capitalization of $1.11 billion, a price-to-earnings ratio of 29.81 and a beta of 0.43.
VanEck Pharmaceutical ETF Cuts Dividend
The business also recently announced a quarterly dividend, which was paid on Tuesday, October 6th. Investors of record on Thursday, October 1st were paid a $0.36 dividend. The ex-dividend date was Thursday, October 1st. This is a drop from VanEck Pharmaceutical ETF’s previous quarterly dividend of $0.6248. This represents a $1.44 annualized dividend and a dividend yield of 1.2%.
About VanEck Pharmaceutical ETF
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
Further Reading
- Five stocks we like better than VanEck Pharmaceutical ETF
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Want to see what other hedge funds are holding PPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report).
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.
